financetom
Business
financetom
/
Business
/
Novo Nordisk ready to launch oral semaglutide in US in 2026, executive says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Novo Nordisk ready to launch oral semaglutide in US in 2026, executive says
Sep 17, 2025 3:09 AM

COPENHAGEN, Sept 17 (Reuters) - Novo Nordisk

is prepared for a full-fledged launch of oral semaglutide in the

United States in 2026, the group's head of product and portfolio

strategy told Reuters on Wednesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Avidbank Holdings to Launch IPO
Avidbank Holdings to Launch IPO
Aug 4, 2025
07:52 AM EDT, 08/04/2025 (MT Newswires) -- Avidbank Holdings ( AVBH ) said Monday it plans to launch its initial public offering of about 2.6 million shares, which may be priced between $22 and $24 per share. Underwriters are expected to be granted a 30-day option to buy up to an additional 391,500 shares. Avidbank Holdings ( AVBH ), the...
Crypto firm Bullish seeks up to $4.2 billion valuation in US IPO
Crypto firm Bullish seeks up to $4.2 billion valuation in US IPO
Aug 4, 2025
(Reuters) -Crypto exchange Bullish is targeting a valuation of up to $4.23 billion in its United States listing, the company said in a filing on Monday, launching its roadshow to capitalize on the momentum built by digital assets amid regulatory clarity. The company is seeking up to $629.3 million by offering 20.3 million shares priced between $28 and $31 each....
Xoma Royalty to Acquire Lava Therapeutics for $1.16 to $1.24 per Share Plus Contingent Value Right
Xoma Royalty to Acquire Lava Therapeutics for $1.16 to $1.24 per Share Plus Contingent Value Right
Aug 4, 2025
08:14 AM EDT, 08/04/2025 (MT Newswires) -- Xoma Royalty ( XOMA ) said Monday it entered a deal to acquire Lava Therapeutics ( LVTX ) for between $1.16 and $1.24 per share plus a non-transferable contingent value right per share. The contingent value right per share represents a right to receive 75% of net proceeds tied to two of Lava's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved